Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other analysts have also recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and set a $40.00 price objective on shares of Dova Pharmaceuticals in a research report on Sunday, July 15th. Leerink Swann cut Dova Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, July 9th. Zacks Investment Research cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 16th. Raymond James initiated coverage on Dova Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $44.00 price objective for the company. Finally, ValuEngine cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $35.20.

Shares of DOVA stock opened at $25.28 on Friday. Dova Pharmaceuticals has a 1-year low of $20.65 and a 1-year high of $37.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.19 and a quick ratio of 13.14.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.07). The firm had revenue of $4.58 million during the quarter. equities analysts expect that Dova Pharmaceuticals will post -2.79 earnings per share for the current year.

In related news, CEO Alex Sapir purchased 21,700 shares of Dova Pharmaceuticals stock in a transaction on Tuesday, August 14th. The stock was bought at an average price of $22.83 per share, with a total value of $495,411.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul B. Manning purchased 120,000 shares of Dova Pharmaceuticals stock in a transaction on Tuesday, June 5th. The stock was bought at an average cost of $26.17 per share, with a total value of $3,140,400.00. The disclosure for this purchase can be found here. Insiders acquired 328,400 shares of company stock valued at $8,965,593 in the last ninety days. Insiders own 55.50% of the company’s stock.

Several large investors have recently made changes to their positions in DOVA. BlackRock Inc. lifted its position in shares of Dova Pharmaceuticals by 76.5% during the 2nd quarter. BlackRock Inc. now owns 1,144,920 shares of the company’s stock worth $34,257,000 after purchasing an additional 496,306 shares during the last quarter. Nexthera Capital LP lifted its position in shares of Dova Pharmaceuticals by 44.4% during the 2nd quarter. Nexthera Capital LP now owns 820,348 shares of the company’s stock worth $24,545,000 after purchasing an additional 252,105 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Dova Pharmaceuticals by 12.7% during the 2nd quarter. Wells Fargo & Company MN now owns 380,455 shares of the company’s stock worth $11,383,000 after purchasing an additional 42,819 shares during the last quarter. Pier Capital LLC lifted its position in shares of Dova Pharmaceuticals by 36.1% during the 1st quarter. Pier Capital LLC now owns 217,885 shares of the company’s stock worth $5,909,000 after purchasing an additional 57,762 shares during the last quarter. Finally, GW&K Investment Management LLC acquired a new position in shares of Dova Pharmaceuticals during the 1st quarter worth about $3,875,000. 36.53% of the stock is owned by institutional investors.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Featured Story: Stock Symbol

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.